AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00162955
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
Trial: NCT00629278
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00629278
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00629278
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00629278
Drug: releasing hormone agonist therapy
RxNorm normalized name: thyrotropin-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00629278
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03441217
Drug: Hyoscine Butylbromide 20Mg/1mL Injection
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
Trial: NCT03441217
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
Trial: NCT02097017
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will local application of lidocaine to the cervix alleviate pain of laminaria insertion
Trial: NCT04537780
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily at bed time.
Trial: NCT00974142
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
Trial: NCT04034368
Drug: Tenofovir Alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
Trial: NCT00373386
Drug: growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone treatment
Trial: NCT00007592
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00273338
Drug: calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00273338
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01120366
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
Trial: NCT04070781
Drug: Itacitinib
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles
Trial: NCT04070781
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles
Trial: NCT04617782
Drug: Aricept
RxNorm normalized name: Aricept
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04414995
Drug: Paracetamol injection and normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of paracetamol and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Trial: NCT00028483
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001572
Drug: Id-KLH Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001572
Drug: QS-21 (Stimulation-QS-21) Drug
DrugBank: QS-21 (DB05400)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00186186
Drug: Depakote ER
RxNorm normalized name: Depakote ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Depakote ER
Trial: NCT03291847
Drug: Buprenorphine Naloxone
RxNorm normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment for opioid use disorder
Trial: NCT02100371
Drug: BMS-833923
RxNorm normalized name: BMS-833923
DrugBank: BMS-833923 (DB16844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
Trial: NCT00325013
Drug: Docosahexaenoic Acid (DHA)
RxNorm normalized name: Docosahexaenoic Acid (DHA)
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mg twice a day for 1 year
Trial: NCT02828254
Drug: PRI-724
RxNorm normalized name: PRI-724
DrugBank: PRI-724 (DB15034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01385891
Drug: Clofarabine VP 16 ciclophospahamide
RxNorm normalized name: etoposide
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
Trial: NCT00092105
Drug: MK0476, montelukast sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02120911
Drug: Pertuzumab, trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
Trial: NCT00346151
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
Trial: NCT02413918
Drug: iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
Trial: NCT00346151
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
Trial: NCT02518568
Drug: V0355
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration (2 tablets)
Trial: NCT01322100
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
Trial: NCT01412177
Drug: OTO-104
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of 12 mg OTO-104
Trial: NCT04388111
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg of Morphine delivered Intraosseously
Trial: NCT00799682
Drug: Xalatan
RxNorm normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
Trial: NCT00799682
Drug: Travatan Z
RxNorm normalized name: Travatan Z
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
Trial: NCT01419795
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00367250
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly i.v.
Trial: NCT00367250
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly i.v.
Trial: NCT00008008
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01342913
Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhalation Powder
Trial: NCT01342913
Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhalation Powder
Trial: NCT00683878
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
Trial: NCT00683878
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
Trial: NCT00683878
Drug: Placebo matching Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, 0 mg, once daily, up to 48 weeks
Trial: NCT00683878
Drug: Thiazolidinedione (Pioglitazone)
RxNorm normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, ≥ 30 mg, Once daily, up to 48 weeks
Trial: NCT02773381
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration once-daily.
Trial: NCT02682381
Drug: Teduglutide 0.05mg/kg
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05 mg/kg
Trial: NCT02682381
Drug: Teduglutide 0.025 mg/kg
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.025 mg/kg
Trial: NCT00769886
Drug: Ketotifen/naphazoline
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
Trial: NCT00769886
Drug: Ketotifen
RxNorm normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of Ketotifen in study eye at visit 3 and visit 4.
Trial: NCT00769886
Drug: Naphazoline
RxNorm normalized name: Naphazoline
DrugBank: Naphazoline (DB06711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of naphazoline in study eye at vist 3 and visit 4.
Trial: NCT00346151
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
Trial: NCT00346151
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
Trial: NCT00230399
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00992173
Drug: Ultratrace Iobenguane I 131
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
Trial: NCT04001517
Drug: Neflamapimod
RxNorm normalized name: Neflamapimod
DrugBank: Neflamapimod (DB07138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-Blind, Placebo-Controlled
Trial: NCT00461617
Drug: Mitiglinide
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 10mg tablet, 10mg TID
Trial: NCT00851357
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
Trial: NCT01288755
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
Trial: NCT01911169
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 International units versus 400 international units as an active comparator
Trial: NCT02600520
Drug: SRP with RSV gel LDD
RxNorm normalized name: Q-Gel with Lipoic Acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
Trial: NCT02600520
Drug: SRP with ATV gel LDD
RxNorm normalized name: Q-Gel with Lipoic Acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
Trial: NCT03567369
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 4,0 mg/mL
Trial: NCT04353102
Drug: YH002
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.
Trial: NCT02038868
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03594396
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300mg bid will be given on days 1-28 days without rest.
Trial: NCT03594396
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
Trial: NCT00396513
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00983242
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
Trial: NCT00983242
Drug: Verapamil HCl ER
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
Trial: NCT00983242
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
Trial: NCT01389076
Drug: Bexxar
RxNorm normalized name: Bexxar Dosimetric
DrugBank: Tositumomab (DB00081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body.
Trial: NCT01779271
Drug: Pelubiprofen
RxNorm normalized name: pelubiprofen
DrugBank: Pelubiprofen (DB12150)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01779271
Drug: Loxoprofen
RxNorm normalized name: Loxoprofen
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT03985878
Drug: Eteplirsen
RxNorm normalized name: Eteplirsen
DrugBank: Eteplirsen (DB06014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eteplirsen IV infusion once weekly.
Trial: NCT00003899
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003899
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003899
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00394277
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 µg sc weekly for 48 weeks
Trial: NCT01517932
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery
Trial: NCT03016312
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
Trial: NCT03016312
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
Trial: NCT03450863
Drug: Fast-acting insulin aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection \[MDI\]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion \[CSII\]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
Trial: NCT01840007
Drug: Metformin Group
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken.
Trial: NCT00900510
Drug: Trimethoprim/Sulfamethoxazole (Bactrim)
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim/Sulfamethoxazole, oral